2023
Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease
Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.Peer-Reviewed Original ResearchPeripheral bloodT cellsAlzheimer's diseaseEM CD8Memory CD8Gene signatureAge-related immune changesIL-7 receptor alphaEffector memory CD8Strong risk factorT cell expansionAD genesAge-associated expansionImmune changesRisk factorsCD8Dementia patientsIL-7RNeuropsychological testingReceptor alphaNeurocognitive functionRT-qPCR resultsDisease severityPatientsNormal persons
2021
Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR
Sánchez-Zuno GA, Bucala R, Hernández-Bello J, Román-Fernández IV, García-Chagollán M, Nicoletti F, Matuz-Flores MG, García-Arellano S, Esparza-Michel JA, Cerpa-Cruz S, Pérez-Guerrero EE, Muñoz-Valle JF. Canonical (CD74/CD44) and Non-Canonical (CXCR2, 4 and 7) MIF Receptors Are Differentially Expressed in Rheumatoid Arthritis Patients Evaluated by DAS28-ESR. Journal Of Clinical Medicine 2021, 11: 120. PMID: 35011861, PMCID: PMC8745239, DOI: 10.3390/jcm11010120.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorHigh disease activityDisease activityDAS28-ESRControl subjectsClinical activityRA clinical activityRheumatoid arthritis patientsExpression of CD74Expression of CXCR4Migration inhibitory factorScavenger-type receptorsDifferent clinical activitiesRA patientsMIF receptorArthritis pathogenesisArthritis patientsCXCR7 expressionInflammatory conditionsReceptor expressionPatientsB cellsDecoy receptorInhibitory factorSoluble CD74Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis
Poulsen KL, Fan X, Kibler CD, Huang E, Wu X, McMullen MR, Leng L, Bucala R, Ventura-Cots M, Argemi J, Bataller R, Nagy LE. Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis. JCI Insight 2021, 6: e141420. PMID: 33945507, PMCID: PMC8262327, DOI: 10.1172/jci.insight.141420.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorAlcohol-associated hepatitisChemokine expressionHealthy controlsLiver diseaseRole of MIFMIF KO miceChronic liver diseaseCytokines/chemokinesMigration inhibitory factorUpstream regulatorChemokine signatureChemokine CCL20WT miceCultured hepatocytesMultiple chemokinesChemokine systemInflammatory responseChemokine membersNovel therapiesEthanol feedingPatientsChemokine familyChemokinesInhibitory factor
2019
2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility
Odio C, Leng L, Siu E, Piecychna M, Galgiani J, Holland S, Bucala R. 2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility. Open Forum Infectious Diseases 2019, 6: s903-s903. PMCID: PMC6810323, DOI: 10.1093/ofid/ofz360.2276.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorPlasma MIF levelsHigh MIF expressionMigration inhibitory factorHuman lung epithelial cellsMIF expressionDisseminated coccidioidomycosisHealthy controlsLung epithelial cellsMIF levelsHigh-expression MIF allelesInhibitory factorEpithelial cellsFisher's exact testCATT5-8MIF polymorphismsSelf-identified African AmericansInflammatory cytokinesMIF allelesGranulomatous diseaseLow-expression allelePromoter polymorphismCoccidioidomycosis patientsPatientsExact test
2009
MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATION
Meyer-Siegler K, Cox J, Leng L, Bucala R, Vera P. MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATION. Journal Of Urology 2009, 181: 304. DOI: 10.1016/s0022-5347(09)60867-3.Peer-Reviewed Original Research
2006
Immunosuppressive Factors in Cancer
Moss J, Metz C, Bucala R. Immunosuppressive Factors in Cancer. 2006 DOI: 10.1002/3527600906.mcb.200400129.Peer-Reviewed Original ResearchImmunosuppressive factorsTumor cellsHost's antitumor defenseHost immune responseHost immune systemSuccessful cancer therapeuticsCancer patientsAntitumor defenseImmune responseEffective treatmentEvasive mechanismsImmune systemCell surface receptorsCancer therapeuticsSurface receptorsCancerCellsPatientsCytokinesProstaglandinsAntigenMajor obstacleReceptors
2001
Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients
Al-Abed Y, VanPatten S, Li H, Lawson J, FitzGerald G, Manogue K, Bucala R. Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients. Molecular Medicine 2001, 7: 619-623. PMID: 11778651, PMCID: PMC1950073, DOI: 10.1007/bf03401868.Peer-Reviewed Original ResearchConceptsDiabetic patientsDiabetes mellitusPredictor of prognosisBlood glucose levelsNormal patientsGlucose levelsPatientsUseful markerNormal individualsPathologic situationsOxidative stressMellitusAdditional markersΒ-globin chainsLiquid chromatography-mass spectroscopyΒ-chainMarkersHigh levelsPrognosisDiseaseDiagnosis
2000
Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1998
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products
Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 7643-7647. PMID: 9636203, PMCID: PMC22709, DOI: 10.1073/pnas.95.13.7643.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsLow-density lipoproteinGlycation end productsLDL receptorAGE modificationAbnormal lipoprotein profilesGlycation of LDLInability of LDLPrevious immunochemical studiesRenal failureLipoprotein profileTime-dependent decreaseCardiovascular diseaseApolipoprotein BAdvanced glycationDensity lipoproteinReceptor-binding siteEnd productsImmunochemical studiesEpitopesGlycationCellular uptakeMultiple sitesPatientsDiabetesAdvanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis
Chou S, Wang H, Taniguchi A, Bucala R. Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis. Molecular Medicine 1998, 4: 324-332. PMID: 9642682, PMCID: PMC2230387, DOI: 10.1007/bf03401739.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisSporadic amyotrophic lateral sclerosisNeurofilament proteinNeuronal inclusionsLateral sclerosisAGE formationNitric oxide-mediated responsesAnti-AGE antibodyAdvanced glycation endproductsMethodsParaffin sectionsMotor neuronsConclusionsThese dataAdvanced glycationGlycation endproductsNeuronal toxicityNitric oxideSpecific antibodiesProtein nitrationConcomitant inductionSclerosisSuperoxide dismutasePatientsAntibodiesPotent oxidantFree radicalsProtein Glycation and Diabetic Vascular Disease
Bucala R, Rahbar S. Protein Glycation and Diabetic Vascular Disease. Endocrine Updates 1998, 1: 159-180. DOI: 10.1007/978-1-4615-5569-8_9.Peer-Reviewed Original ResearchVascular diseaseNon-insulin dependent diabeticsAtherosclerotic vascular diseaseEnd-organ complicationsDiabetic vascular diseaseDiabetic glucose controlOverall morbidityDependent diabeticsGlucose controlPersistent hyperglycemiaDiabetic complicationsComplicationsUnderlying causeProtein glycationDiseaseDiabeticsMorbidityHyperglycemiaRetinopathyPatientsMortality
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobaccoReduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.Peer-Reviewed Original ResearchConceptsAdvanced glycation endoproductsLow density lipoprotein clearanceLong-term hemodialysis therapyRenal replacement treatmentEffect of hemodialysisAGE removalDiabetic ESRDSerum apoBESRD patientsRenal insufficiencyClinical outcomesLipoprotein clearancePlasma apoBHemodialysis therapyReplacement treatmentApoliprotein BPatientsGroup subjectsHemodialysis filtersReactive substancesApoBPlasma apolipoproteinsAGE clearanceBaselineClearanceRegulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome
Donnelly S, Haslett C, Reid P, Grant I, Wallace W, Metz C, Bruce L, Bucala R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 1997, 3: 320-323. PMID: 9055860, DOI: 10.1038/nm0397-320.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeMigration inhibitory factorRespiratory distress syndromeDistress syndromeSignificant pro-inflammatory effectsInhibitory factorMacrophage migration inhibitory factorPro-inflammatory cytokine secretionPulmonary inflammatory responseAnti-inflammatory actionAnti-inflammatory effectsPro-inflammatory effectsIL-8 secretionConcentration-related fashionNovel therapeutic approachesInflammatory diseasesCytokine secretionInflammatory responseTherapeutic approachesAlveolar airspaceAlveolar cellsPatientsGlucocorticoidsSyndromeSecretionLipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis
Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.Peer-Reviewed Original ResearchLow-density lipoproteinDiabetic patientsLDL levelsElevated LDL levelsEnzyme-linked immunosorbent assay (ELISA) techniqueRecent clinical observationsAdvanced glycosylation reactionsImmunosorbent assay (ELISA) techniqueVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallClearance mechanismsNitric oxidePatientsRadical generating systemELISA analysisAgeLipoproteinOxidative modification
1996
What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoproteinThe role of advanced glycosylation end-products in the pathogenesis of atherosclerosis
Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrology Dialysis Transplantation 1996, 11: 31-33. PMID: 9044304, DOI: 10.1093/ndt/11.supp5.31.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseLow-density lipoproteinDiabetic patientsDevelopment of atherosclerosisAGE-LDLAdvanced glycosylationAGE-modified formCoronary artery diseaseSerum total cholesterolPathogenesis of atherosclerosisArtery diseaseDiabetes mellitusRenal diseaseTotal cholesterolCerebrovascular diseaseMarked elevationRapid progressionTissue injuryVascular pathologyNormal controlsPatientsAGE-modified peptidesAtherogenic formAtherosclerosisAGE modification
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes
1988
Labile T-wave changes caused by respiratory variation in a patient with unstable angina
Bucala R, Loh E, Wang P, Rutherford J. Labile T-wave changes caused by respiratory variation in a patient with unstable angina. International Journal Of Cardiology 1988, 19: 260-262. PMID: 3372087, DOI: 10.1016/0167-5273(88)90087-3.Peer-Reviewed Original Research
1985
Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosus
Lahita R, Bucala R, Bradlow H, Fishman J. Determination of 16 alpha‐hydroxyestrone by radioimmunoassay in systemic lupus erythematosus. Arthritis & Rheumatism 1985, 28: 1122-1127. PMID: 4052123, DOI: 10.1002/art.1780281007.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusActive diseaseLupus erythematosusInactive systemic lupus erythematosusVariety of seraInactive diseaseSLE patientsAntibody levelsComplement levelsRheumatic diseasesLaboratory criteriaAlpha-hydroxyestroneHormone levelsHealthy volunteersNormal controlsPatientsEstrogenic metabolitesNormal levelsDiseaseErythematosusSignificant increaseRadioimmunoassayPoor correlationMetabolitesHigh levels